Merck & Co., Inc.
Merck & Co., Inc.
Your view on MRK
Overview
What the company does, where it operates, and who runs it.
About Merck & Co., Inc.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Robert M. Davis
- Headquarters
- 2000 Galloping Hill Road, Rahway, NJ, US
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Robert M. Davis
- Headquarters
- 2000 Galloping Hill Road, Rahway, NJ, US
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health.
The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.
It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers.
The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Merck & Co., Inc. from FRC's valuation model, read against the market price. MRK last traded at $144.46, 147.4× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Merck & Co., Inc.. Starting points for Merck & Co., Inc.: P/E 147.4, EPS $0.99, beta 0.22 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Merck & Co., Inc.. Merck & Co., Inc. paid $3.40 per share over the last year — a 2.4% yield at the current $144.46 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Merck & Co., Inc.. Trailing twelve-month EPS for Merck & Co., Inc. stands at $0.99. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$159.00
average of 21 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy15
- Hold6
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $1.75 | $2.13 | $2.79 | $8.90 |
| Low estimate | $1.69 | $2.09 | $2.51 | $8.44 |
| High estimate | $1.87 | $2.17 | $3.00 | $9.36 |
| No. of analysts | 12 | 5 | 14 | 14 |
| Year-ago EPS | $2.04 | -$1.28 | $7.28 | — |
| Growth | -14.4% | +266.3% | -61.7% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $16.29B | $16.46B | $67.25B | $69.42B |
| Low estimate | $16.06B | $16.23B | $66.97B | $68.71B |
| High estimate | $16.49B | $16.72B | $67.65B | $70.16B |
| No. of analysts | 10 | 4 | 18 | 18 |
| Year-ago revenue | $16.32B | $16.29B | $64.93B | — |
| Growth | -0.2% | +1.1% | +3.6% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0, MarketWatch; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Merck & Co., Inc.. Merck & Co., Inc. has reported as a listed company since 1978. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ABBVAbbVie Inc.Drug Manufacturers - General$520.9B
- AMGNAmgen Inc.Drug Manufacturers - General$250.1B
- AZNAstraZeneca PLCDrug Manufacturers - General$285.4B
- GILDGilead Sciences, Inc.Drug Manufacturers - General$207.9B
- JNJJohnson & JohnsonDrug Manufacturers - General$687.9B
- LLYEli Lilly and CompanyDrug Manufacturers - General$1.3T
- NVSNovartis AGDrug Manufacturers - General$302.6B
- PFEPfizer Inc.Drug Manufacturers - General$164.5B
More Drug Manufacturers - General companies
- ALPMYAstellas Pharma Inc.OTC$29.2B
- AMRNAmarin Corporation plcNASDAQ$234M
- BAYRYBayer AGOTC$49.0B
- BIIBBiogen Inc.NASDAQ$37.2B
- BMYBristol-Myers Squibb CompanyNYSE$128.6B
- CHGCFChugai Pharmaceutical Co., Ltd.OTC$105.3B
- CHGCYChugai Pharmaceutical Co., Ltd.OTC$110.0B
- CHJTFCSPC Pharmaceutical Group LimitedOTC$15.8B
- CSPCYCSPC Pharmaceutical Group LimitedOTC$14.6B
- DSKYFDaiichi Sankyo Company, LimitedOTC$34.1B
ETFs holding Merck & Co., Inc.
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.56%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.51%
- IVViShares Core SP 500 ETF$852.9B in assets0.56%
- SCHDSchwab U.S. Dividend Equity ETF$119.9B in assets3.73%
- PPHVanEck Pharmaceutical ETF$1.1B in assets11.97%
- IYHiShares US Healthcare ETF$4.7B in assets5.17%
- VHTVanguard Health Care ETF$19.1B in assets4.77%
- FHLCFIDELITY MSCI HEALTH CARE INDEX ETF$4.0B in assets4.58%
Largest holders first, then the funds most concentrated in MRK.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Merck & Co., Inc., and how their positions are changing. At a $356.13B market value, institutional positions materially move Merck & Co., Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Merck & Co., Inc. executives and directors. Shares of Merck & Co., Inc. have traded between $73.31 and $105.07 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Merck & Co., Inc.. Merck & Co., Inc. is a $356.13B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Merck & Co., Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Merck & Co., Inc.. Coverage tracks Merck & Co., Inc. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Merck & Co., Inc.